Andrzej Eljaszewicz1, Fiorella Ruchti2, Urszula Radzikowska1, Anna Globinska2, Tadech Boonpiyathad3, Anna Gschwend4, Hideaki Morita5, Arthur Helbling4, Stefania Arasi6, Helga Kahlert7, Nadine Berek7, Andreas Nandy7, Mübeccel Akdis8, Christoph Willers7, Marcin Moniuszko9, Cezmi A Akdis2, Milena Sokolowska10. 1. Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland. 2. Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland. 3. Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland; Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand; Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 4. University Clinic for Rheumatology, Immunology and Allergology, Insel Hospital, University Hospital Bern, Bern, Switzerland. 5. Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland; Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan. 6. Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Pediatric Allergology Unit, Department of Pediatric Medicine, Bambino Gesù Children's Research Hospital (IRCCS), Rome, Italy. 7. Allergopharma GmbH & Co KG, Reinbek, Germany. 8. Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland. 9. Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland; Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland. 10. Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland. Electronic address: milena.sokolowska@siaf.uzh.ch.
Abstract
BACKGROUND: Despite the efficacy of allergen-specific immunotherapy (AIT), the role of trained immunity and tolerance in this process has not been elucidated. OBJECTIVE: Here, we have performed a comprehensive longitudinal analysis of the systemic innate immune cell repertoire during the course of AIT. METHODS: Patients with allergy received standard preseasonal subcutaneous AIT with allergoids to birch and/or grass. Healthy controls were monitored without any intervention. Flow cytometry of innate lymphoid cell (ILC), natural killer cell, monocyte cell, and dendritic cell (DC) subsets was performed at baseline, 3 months (birch season), 6 months (grass seasons), and 12 months after the therapy in patients or at similar seasonal time points in controls. Additional analyses were performed in the third-year birch and grass season. RESULTS: We observed a durable decrease in group 2 ILCs and an increase of group 1 ILCs after AIT, with dynamic changes in their composition. We found that an expansion of CD127+CD25++ clusters caused observed shifts in the heterogeneity of group 1 ILCs. In addition, we observed development of CD127+CD25++c-Kit+ group 3 ILC clusters. Moreover, we found an increase in the number of intermediate monocytes in parallel with a reduction in nonclassical monocytes during the first year after AIT. Classical and intermediate monocytes presented significant heterogeneity in patients with allergy, but AIT reduced the HLA-DR++ clusters. Finally, an increase in plasmacytoid DCs and CD141+ myeloid DCs was observed in individuals with allergy, whereas the number of CD1c+ myeloid DCs was reduced during the first year of AIT. CONCLUSION: AIT induces changes in the composition and heterogeneity of circulating innate immune cells and brings them to the level observed in healthy individuals. Monitoring of ILCs, monocytes, and DCs during AIT might serve as a novel biomarker strategy.
BACKGROUND: Despite the efficacy of allergen-specific immunotherapy (AIT), the role of trained immunity and tolerance in this process has not been elucidated. OBJECTIVE: Here, we have performed a comprehensive longitudinal analysis of the systemic innate immune cell repertoire during the course of AIT. METHODS:Patients with allergy received standard preseasonal subcutaneous AIT with allergoids to birch and/or grass. Healthy controls were monitored without any intervention. Flow cytometry of innate lymphoid cell (ILC), natural killer cell, monocyte cell, and dendritic cell (DC) subsets was performed at baseline, 3 months (birch season), 6 months (grass seasons), and 12 months after the therapy in patients or at similar seasonal time points in controls. Additional analyses were performed in the third-year birch and grass season. RESULTS: We observed a durable decrease in group 2 ILCs and an increase of group 1 ILCs after AIT, with dynamic changes in their composition. We found that an expansion of CD127+CD25++ clusters caused observed shifts in the heterogeneity of group 1 ILCs. In addition, we observed development of CD127+CD25++c-Kit+ group 3 ILC clusters. Moreover, we found an increase in the number of intermediate monocytes in parallel with a reduction in nonclassical monocytes during the first year after AIT. Classical and intermediate monocytes presented significant heterogeneity in patients with allergy, but AIT reduced the HLA-DR++ clusters. Finally, an increase in plasmacytoid DCs and CD141+ myeloid DCs was observed in individuals with allergy, whereas the number of CD1c+ myeloid DCs was reduced during the first year of AIT. CONCLUSION: AIT induces changes in the composition and heterogeneity of circulating innate immune cells and brings them to the level observed in healthy individuals. Monitoring of ILCs, monocytes, and DCs during AIT might serve as a novel biomarker strategy.
Authors: Nathalie Acevedo; Bilal Alashkar Alhamwe; Luis Caraballo; Mei Ding; Antonio Ferrante; Holger Garn; Johan Garssen; Charles S Hii; James Irvine; Kevin Llinás-Caballero; Juan Felipe López; Sarah Miethe; Khalida Perveen; Elke Pogge von Strandmann; Milena Sokolowska; Daniel P Potaczek; Betty C A M van Esch Journal: Nutrients Date: 2021-02-25 Impact factor: 5.717
Authors: Naima G Cortes-Perez; Alejandra de Moreno de LeBlanc; Jorge G Gomez-Gutierrez; Jean Guy LeBlanc; Luis G Bermúdez-Humarán Journal: Biomolecules Date: 2021-09-24
Authors: Marek Jutel; Maria J Torres; Oscar Palomares; Cezmi A Akdis; Thomas Eiwegger; Eva Untersmayr; Domingo Barber; Magdalena Zemelka-Wiacek; Anna Kosowska; Elizabeth Palmer; Stefan Vieths; Vera Mahler; Walter G Canonica; Kari Nadeau; Mohamed H Shamji; Ioana Agache Journal: Allergy Date: 2022-03-18 Impact factor: 14.710
Authors: Katarzyna Ptaszyńska-Kopczyńska; Andrzej Eljaszewicz; Marta Marcinkiewicz-Siemion; Emilia Sawicka-Śmiarowska; Ewa Tarasiuk; Anna Lisowska; Marlena Tynecka; Kamil Grubczak; Urszula Radzikowska; Adrian Janucik; Marcin Moniuszko; Karol Charkiewicz; Piotr Laudański; Bożena Sobkowicz; Karol A Kamiński Journal: Cells Date: 2021-12-09 Impact factor: 6.600